C12N 2770/00071
Demonstrated in vivo effect
C12N2770/00071 (Demonstrated in vivo effect) appears on 4 US grants and 6 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 6
- Assignees
- 5
- Inventors
- 17
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 0 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 0 |
By publication year.
Recent patents
- Cancer immunotherapy using virus particles8 Jul 2025US 12,350,326 B2Case Western Reserve University
- Cancer immunotherapy using virus particles22 Aug 2023US 11,730,803 B2Case Western Reserve University
- Cancer immunotherapy using virus particles1 Mar 2022US 11,260,121 B2Case Western Reserve University
- Cancer immunotherapy using virus particles5 May 2020US 10,639,363 B2Case Western Reverse University
- Cancer immunotherapy using virus particles25 Jan 2024US 2024/0024452 A1Case Western Reserve University
- Anti-tim3 single-chain antibody and use thereof in preparing medicine for treating tumor21 Sep 2023US 2023/0295294 A1Beijing Neurosurgical Institute
- Cancer immunotherapy using virus particles26 Jan 2023US 2023/0024508 A1Case Western Reserve University
- SARS-CoV-2 Vaccines11 Nov 2021US 2021/0346492 A1Janssen Pharmaceuticals, Inc.
- Cancer immunotherapy using virus particles25 Feb 2021US 2021/0052717 A1Case Western Reserve University
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.